ABBV Forecast



Bearish<—>Bullish



80% Confidence




Bullish Case: AbbVie’s strong pipeline, including Skyrizi and Rinvoq, provides robust offset to Humira's decline. Recent acquisitions and successful trials bolster growth potential.




Bearish Case: Humira's biosimilar competition and high R&D costs continue to pressure revenues. Legal challenges and the Cerevel setback elevate financial risks.




Potential Outcomes:
  1. 60% chance: New drug approvals boost stock price significantly.
  2. 30% chance: Humira's sales decline affects financial stability.
  3. 10% chance: Legal issues impact market confidence.




Trading Oracle: Trade a bullish short-term credit spread: sell $170 puts and buy $165 puts expiring in ~30 days. High profit probability due to current volatility backwardation and strong sentiment indicators, leveraging Helium's positive edge.



January 23, 2025


Abbvie Forecast

ABBV        Abbvie
















Become a more profitable investor with AI optimized trading strategies






×

Chat with ABBV


 Ask any question about ABBV!